NEOG Neogen (NEOG) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · In vitro & in vivo diagnostic substances · CIK 0000711377
C-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
150
13F, latest reported quarter
Conversions, 180 days
3
Codes C/M, not in net · $373.7K priced
What the filings say about NEOG
Insiders, 180 days
+$10.4K net bought
1 buyer
Neogen insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, NEOGEN CORP insiders bought a net $10.4K of stock across 50 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 buys), the last on Aug 4, 2026.
- -5.6% median (+4.8% mean) 90-day return after 5 previous buys.
- The trade is 32.0% of the 1,579 shares held after it.
- No other insider bought within 30 days.
- 150 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO Nassif Mikheal bought about $6.0K of NEOG on Oct 9, 2026, the largest insider purchase at the company since 2025; 150 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 buys), the last on Feb 17, 2026.
- -5.6% median (+4.8% mean) 90-day return after 5 previous buys.
- The trade is 34.5% of the 1,074 shares held after it.
- No other insider bought within 30 days.
- 150 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO Nassif Mikheal bought about $4.4K of NEOG on Aug 4, 2026, the largest insider purchase at the company since 2025; 150 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on Feb 2, 2026.
- -2.9% median (+11.5% mean) 90-day return after 4 previous buys.
- The trade is 3.3% of the 704 shares held after it.
- No other insider bought within 30 days.
- 150 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO Nassif Mikheal bought about $252 of NEOG on Feb 17, 2026; 150 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Jan 26, 2026.
- -0.1% median (+19.1% mean) 90-day return after 3 previous buys.
- The trade is 3.5% of the 681 shares held after it.
- No other insider bought within 30 days.
- 150 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO Nassif Mikheal bought about $240 of NEOG on Feb 2, 2026; 150 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Jan 16, 2026.
- +31.4% median (+31.4% mean) 90-day return after 2 previous buys.
- The trade is 3.8% of the 657 shares held after it.
- No other insider bought within 30 days.
- 150 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO Nassif Mikheal bought about $246 of NEOG on Jan 26, 2026; 150 funds added in the latest 13F quarter.50 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$10.4K over 180 days
+$10.4K over 90 days
more than 67% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
150 funds bought in last quarter
more than 81% of Pharma & Biotech
Revenue
-2.7% year over year
below 60% of Pharma & Biotech
Margin
-0.9% net margin
more than 72% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
5.5% of the float short (float per yahoo 2026-10-27) · 2.5 days to cover · settled 2026-10-15
more than 54% of Pharma & Biotech
What changed in the last 30 days
Oct 9CEO Nassif Mikheal bought $6.0K (Oct 9)
Watch NEOG
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+101.2%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns NEOG: institutional holders (13F)
13F holdings, latest reported quarter
33,431,015 sh
$300.5M
16,570,795 sh
$149.0M
13,038,732 sh
$117.2M
9,828,174 sh
$88.4M
9,655,248 sh
$86.8M
Congress trades in NEOG
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
NEOG planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
NEOG mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Clarkston Partners Fund
$7.6M position · as of 2026-06-30
2.6%
ALGER WEATHERBIE SPECIALIZED GROWTH FUND
$5.9M position · as of 2026-07-31
2.5%
Small Cap Equity Portfolio
$18.8M position · as of 2026-07-31
1.8%
Victory RS Partners Fund
$11.3M position · as of 2026-06-30
1.7%
State Street(R) SPDR(R) S&P(R) Health Care Equipment ETF
$2.4M position · as of 2026-06-30
1.6%
BARON SMALL CAP FUND
$45.0M position · as of 2026-06-30
1.6%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2020
$2.5M
$4.6M
$714.9K
+30%
+30%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $10.4K bought by insiders over 180 days, 150 funds added last quarter. Each figure is a federal filing, dated the day it went public.
NEOG financials
Revenue growth
-2.7%
XBRL, annual
Net margin
-0.9%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$884.0M
four quarters, 2025-09-01 to 2026-08-31
Revenue, TTM NEOG
| FY May 2026 | $870.4M |
| FY May 2025 | $894.7M |
| FY May 2024 | $924.2M |
| FY May 2023 | $822.4M |
| FY May 2022 | $527.2M |
| Aug 2026 | $222.8M |
| May 2026 | $225.3M |
| Feb 2026 | $211.2M |
| Nov 2025 | $224.7M |
| Aug 2025 | $209.2M |
| May 2025 | $225.5M |
| Feb 2025 | $221.0M |
| Nov 2024 | $231.3M |
At each fiscal year end
Single quarter
Net margin, TTM
-6.3%
net income over revenue, 2025-09-01 to 2026-08-31
Net margin, TTM NEOG
| FY May 2026 | -0.9% |
| FY May 2025 | -122.0% |
| FY May 2024 | -1.0% |
| FY May 2023 | -2.8% |
| FY May 2022 | +9.2% |
| Aug 2026 | -5.3% |
| May 2026 | -5.0% |
| Feb 2026 | -8.0% |
| Nov 2025 | -7.1% |
| Aug 2025 | +17.4% |
| May 2025 | -271.5% |
| Feb 2025 | -4.9% |
| Nov 2024 | -197.3% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$49.8M
operating cash flow minus capex, 2025-09-01 to 2026-08-31
Free cash flow, TTM NEOG
| FY May 2026 | $31.9M |
| FY May 2025 | -$46.4M |
| FY May 2024 | -$76.1M |
| FY May 2023 | -$24.7M |
| FY May 2022 | $43.6M |
| Aug 2026 | $4.7M |
| May 2026 | $26.2M |
| Feb 2026 | $11.1M |
| Nov 2025 | $7.8M |
| Aug 2025 | -$13.2M |
| May 2025 | $300.0K |
| Feb 2025 | -$13.4M |
| Nov 2024 | $23.1M |
At each fiscal year end
Single quarter
Debt to equity
0.37x
long-term 2026-08-31 plus current 2026-05-31; equity 2026-08-31
Debt to equity NEOG
| FY May 2026 | 0.38x |
| FY May 2025 | 0.43x |
| FY May 2024 | 0.28x |
| FY May 2023 | 0.28x |
| FY May 2022 | 0.00x |
| Aug 2026 | 0.37x |
| May 2026 | 0.38x |
| Feb 2026 | 0.39x |
| Nov 2025 | 0.39x |
| Aug 2025 | 0.38x |
| May 2025 | 0.43x |
| Feb 2025 | 0.34x |
| Nov 2024 | 0.33x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.11x
TTM operating cash flow over long-term 2026-08-31 plus current 2026-05-31
Cash flow to debt NEOG
| FY May 2026 | 0.10x |
| FY May 2025 | 0.07x |
| FY May 2024 | 0.04x |
| FY May 2023 | 0.05x |
| FY May 2022 | n/a |
| Aug 2026 | 0.11x |
| May 2026 | 0.10x |
| Feb 2026 | 0.09x |
| Nov 2025 | 0.08x |
| Aug 2025 | 0.11x |
| May 2025 | 0.07x |
| Feb 2025 | 0.08x |
| Nov 2024 | 0.02x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-2.7%
TTM net income over average of 2025-08-31 and 2026-08-31
Return on equity NEOG
| FY May 2026 | -0.4% |
| FY May 2025 | -41.9% |
| FY May 2024 | -0.3% |
| FY May 2023 | -1.1% |
| FY May 2022 | +5.6% |
| Aug 2026 | -2.7% |
| May 2026 | -0.4% |
| Feb 2026 | -25.6% |
| Nov 2025 | -25.3% |
| Aug 2025 | -39.7% |
| May 2025 | -41.9% |
| Feb 2025 | -16.7% |
| Nov 2024 | -16.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-1.7%
TTM net income over average of 2025-08-31 and 2026-08-31
Return on assets NEOG
| FY May 2026 | -0.2% |
| FY May 2025 | -27.3% |
| FY May 2024 | -0.2% |
| FY May 2023 | -0.8% |
| FY May 2022 | +5.1% |
| Aug 2026 | -1.7% |
| May 2026 | -0.2% |
| Feb 2026 | -16.5% |
| Nov 2025 | -16.3% |
| Aug 2025 | -26.5% |
| May 2025 | -27.3% |
| Feb 2025 | -11.3% |
| Nov 2024 | -11.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital NEOG
| FY May 2026 | n/a |
| FY May 2025 | n/a |
| FY May 2024 | n/a |
| FY May 2023 | n/a |
| FY May 2022 | +5.9% |
| Aug 2026 | n/a |
| May 2026 | n/a |
| Feb 2026 | n/a |
| Nov 2025 | n/a |
| Aug 2025 | n/a |
| May 2025 | n/a |
| Feb 2025 | n/a |
| Nov 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-0.2%
operating income (EBIT proxy) over average of 2025-08-31 and 2026-08-31 minus current liabilities
Return on capital employed NEOG
| FY May 2026 | -0.7% |
| FY May 2025 | -27.7% |
| FY May 2024 | +1.3% |
| FY May 2023 | +1.4% |
| FY May 2022 | +6.6% |
| Aug 2026 | -0.2% |
| May 2026 | -0.7% |
| Feb 2026 | -17.9% |
| Nov 2025 | -17.6% |
| Aug 2025 | -28.4% |
| May 2025 | -27.7% |
| Feb 2025 | -10.5% |
| Nov 2024 | -10.3% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing NEOG
| FY May 2026 | n/a |
| FY May 2025 | n/a |
| FY May 2024 | n/a |
| FY May 2023 | n/a |
| FY May 2022 | 58.80x |
| Aug 2026 | n/a |
| May 2026 | n/a |
| Feb 2026 | n/a |
| Nov 2025 | n/a |
| Aug 2025 | n/a |
| May 2025 | n/a |
| Feb 2025 | n/a |
| Nov 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$3.3B
market value at close 2026-10-26 on 2026-08-31 shares, plus long-term 2026-08-31 plus current 2026-05-31, minus cash 2026-08-31
Enterprise value NEOG
| FY May 2026 | $2.6B |
| FY May 2025 | $2.0B |
| FY May 2024 | $3.6B |
| FY May 2023 | $4.5B |
| FY May 2022 | $2.8B |
| Aug 2026 | $3.1B |
| May 2026 | $2.6B |
| Feb 2026 | $3.1B |
| Nov 2025 | $2.0B |
| Aug 2025 | $1.9B |
| May 2025 | $2.0B |
| Feb 2025 | $2.9B |
| Nov 2024 | $3.8B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+1.9%
TTM free cash flow over market value at close 2026-10-26
FCF yield NEOG
| FY May 2026 | +1.6% |
| FY May 2025 | -3.6% |
| FY May 2024 | -2.7% |
| FY May 2023 | -0.7% |
| FY May 2022 | +1.5% |
| Aug 2026 | +2.0% |
| May 2026 | +1.6% |
| Feb 2026 | +0.2% |
| Nov 2025 | -1.4% |
| Aug 2025 | -0.3% |
| May 2025 | -3.6% |
| Feb 2025 | -2.0% |
| Nov 2024 | -3.0% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing NEOG
| FY May 2026 | n/a |
| FY May 2025 | n/a |
| FY May 2024 | n/a |
| FY May 2023 | n/a |
| FY May 2022 | n/a |
| Aug 2026 | n/a |
| May 2026 | n/a |
| Feb 2026 | n/a |
| Nov 2025 | n/a |
| Aug 2025 | n/a |
| May 2025 | n/a |
| Feb 2025 | n/a |
| Nov 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2026-05 | 2025-05 | 2024-05 | 2023-05 | |
|---|---|---|---|---|
| Revenue | $870.4M | $894.7M | $924.2M | $822.4M |
| Gross profit | $408.5M | $421.4M | $463.9M | $406.0M |
| Operating income | -$21.6M | -$1.1B | $58.6M | $37.5M |
| Net income | -$7.9M | -$1.1B | -$9.4M | -$22.9M |
| EPS (diluted) | -0.04 | -5.03 | -0.04 | -0.12 |
| Operating cash flow | $83.2M | $58.2M | $35.3M | $41.0M |
| Cash | $185.5M | $129.0M | $170.6M | $163.2M |
| Long-term debt | $793.7M | $874.8M | $888.4M | $885.4M |
SEC XBRL, fiscal years, as known on 2026-10-28
NEOG Stock Sonar score 6/7 axes
Find similar shapesCompareNEOG ranks highest on profitability (82nd percentile) and insider conviction (61st), and lowest on risk and compliance (21st), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
NEOG filings, in plain words
Are Neogen insiders buying or selling NEOG?
In the 180 days to 2026-10-28, Neogen insiders were net buyers, a net $10.4K across purchases and sales reported on Form 4, by 1 buyer.
Read the full summary
In the 180 days to 2026-10-28, Neogen insiders were net buyers of NEOG, a net $10.4K across purchases and sales reported on Form 4 by 1 buyer. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
